Bortezomib-induced Sweet's syndrome.
Sweet's syndrome is an uncommon acute skin disease, associated with a variety of medical problems. The drug-induced variant is even rarer. We describe two cases of this syndrome associated with the administration of the proteasome inhibitor bortezomib. The diagnostic criteria for drug-induced Sweet's syndrome as proposed by Walker and Cohen were fulfilled. Vasculitis and neutrophilic eccrine hidradenitis were excluded.
Van Regenmortel
N
N
Division of Haematology, Antwerp University Hospital.
Van de Voorde
K
K
De Raeve
H
H
Rombouts
S
S
Van de Velde
A
A
Lambert
J
J
Schroyens
W
W
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D001897:Boronic Acids / Q000008:administration & dosage / Q000009:adverse effects*; D000069286:Bortezomib; D004334:Drug Administration Schedule; D007172:Erectile Dysfunction / Q000139:chemically induced; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008297:Male; D008558:Melphalan / Q000008:administration & dosage; D008775:Methylprednisolone / Q000627:therapeutic use; D009101:Multiple Myeloma / Q000188:drug therapy; D010146:Pain / Q000139:chemically induced; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced; D011239:Prednisolone / Q000008:administration & dosage; D011480:Protease Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D011719:Pyrazines / Q000008:administration & dosage / Q000009:adverse effects*; D012008:Recurrence; D007319:Sleep Initiation and Maintenance Disorders / Q000139:chemically induced; D016463:Sweet Syndrome / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology; D013733:Testicular Diseases / Q000139:chemically induced
D001897:Boronic Acids; D007166:Immunosuppressive Agents; D011480:Protease Inhibitors; D011719:Pyrazines; D000069286:Bortezomib; D011239:Prednisolone; D008558:Melphalan; D008775:Methylprednisolone